Beam Therapeutics Investor Relations Material
Latest events
Study Update
Beam Therapeutics
Q2 2025
5 Aug, 2025
Q1 2025
6 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Beam Therapeutics Inc
Access all reports
Beam Therapeutics Inc is a biotechnology company focused on the development of precision genetic medicines using base editing technology. The company’s approach aims to correct genetic mutations at the single-base level to treat various diseases, including genetic disorders and cancers. It conducts research and development in-house and through collaborations. Beam Therapeutics Inc is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Beam Therapeutics Inc
Study Update
Beam Therapeutics Inc
Status Update
Beam Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BEAM
Country
🇺🇸 United States